US Patent

US12122789 — Forms of pyrido[1,2-a]pyrimidin-4-one derivatives, its formulation and its process of making

Composition of Matter · Assigned to Hoffmann La Roche Inc · Expires 2041-04-15 · 15y remaining

Vulnerability score 17/100 Ironclad — strong claim type, well-established, deep family

What this patent protects

This patent protects a process for making a specific type of pyrido[1,2-a]pyrimidin-4-one derivative, useful as a pharmaceutically active compound.

USPTO Abstract

The present invention relates to a process for the preparation of 7-(4,7-diazaspiro[2.5]octan-7-yl)-2-(2,8-dimethylimidazo[1,2-b]pyridazin-6-yl)pyrido[1,2-a]pyrimidin-4-one useful as pharmaceutically active compounds.

Drugs covered by this patent

Patent Metadata

Patent number
US12122789
Jurisdiction
US
Classification
Composition of Matter
Expires
2041-04-15
Drug substance claim
Yes
Drug product claim
Yes
Assignee
Hoffmann La Roche Inc
Source
FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.